McKesson (MCK) Joins $5.8 Billion Option Care Health (OPCH) Acquisition. Is the Valuation Justified?
McKesson (MCK) is acquiring Option Care Health (OPCH) for $5.8B, including debt, at $32.05 per share, a 37% premium. McKesson and private equity firm CD&R will own 49% and 51% respectively. The deal expands McKesson's specialty healthcare services. McKesson's Q1 2027 revenue was $105.4B, beating estimates, with adjusted EPS up 20% YoY to $9.93. The company raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00.
How this was made
The 30-second read
Why it matters
The deal creates a larger, integrated specialty‑care platform but introduces execution risk and debt load.
Market read
The announcement is a primary M&A disclosure with material valuation impact for both tickers and signals continued consolidation in the specialty‑healthcare sector.
What to watch
Potential regulatory scrutiny of the combined infusion network and the impact on McKesson's cash flow.
Background
McKesson is diversifying beyond drug distribution into higher‑margin specialty services; the acquisition aligns with its strategic shift.
Ticker impact
McKesson announced a $5.8 billion acquisition of Option Care Health, valuing OPCH at $32.05 per share, a 37% premium.
likely pressure as the market prices in acquisition‑related debt and integration uncertainty
Large‑scale M&A with a premium creates immediate valuation adjustments and integration risk for the acquirer.
Option Care Health shareholders receive a 37% premium in the $5.8 billion acquisition by McKesson.
upward pressure as the premium is priced in and the stock trades toward the deal price
The announced premium is a clear catalyst for a near‑term price rise.
Market effects
Strengthens consolidation trend in specialty pharma and infusion services, may spur further M&A in the sector.
U.S. healthcare services market sees increased M&A activity, modest impact on broader indices.
Limited to U.S. healthcare investors; no immediate global macro effect.
Counterpoint
Integration risk and added debt could depress McKesson's valuation more than the growth upside.
Key entities
- companyMcKesson Corporation
U.S. pharmaceutical distributor expanding into specialty care.
- companyOption Care Health, Inc.
Infusion‑services provider being taken private.
- private equityClayton, Dubilier & Rice
Partner in the acquisition, taking 51% stake.
